Persistence and adherence with mirabegron vs antimuscarinics in overactive bladder: Retrospective analysis of a UK General Practice prescription database-Reference-Cited by-同舟云学术

Persistence and adherence with mirabegron vs antimuscarinics in overactive bladder: Retrospective analysis of a UK General Practice prescription database

Published:2017-09-14 Issue:10 Volume:71 Page:e12996
ISSN:1368-5031
Container-title:International Journal of Clinical Practice
language:en
Short-container-title:Int J Clin Pract

Author:

Wagg Adrian S.¹^ORCID,Foley Steve²,Peters John³,Nazir Jameel⁴,Kool-Houweling Leanne⁵,Scrine Ludmila⁴

Affiliation:

1. Department of Medicine; University of Alberta; Edmonton Alberta Canada

2. Royal Berkshire Hospital; Reading UK

3. Department of Urology; Bart's Health NHS Trust (Whipps Cross Hospital); London UK

4. Astellas Pharma Ltd; Chertsey UK

5. QuintilesIMS; Hoofddorp Netherlands

Funder

Astellas Pharma

Publisher

Hindawi Limited

Subject

General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ijcp.12996/fullpdf

Reference28 articles.

1. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society;Abrams;Neurourol Urodyn,2002

2. Efficacy and adverse events of antimuscarinics for treating overactive bladder: network meta-analyses;Buser;Eur Urol,2012

3. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis;Chapple;Eur Urol,2008

4. Comparative adherence to oxybutynin or tolterodine among older patients;Gomes;Eur J Clin Pharmacol,2012

5. Low persistence of anticholinergic drug use in Sweden;Linner;Eur J Clin Pharmacol,2011

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment Patterns with Mirabegron and Antimuscarinics for Overactive Bladder: A Prospective, Registry Study in Taiwan and South Korea (FAITH);Advances in Therapy;2024-03-02

2. A Retrospective Database Analysis to Investigate Treatment Patterns and Health Care Resource Utilisation in Patients who CYCLe AntiMuscarinics in ENgland (CYCLAMEN);European Urology Focus;2023-10

3. Cost, resource utilization, and treatment-taking behaviors among patients with OAB initiating combination mirabegron and antimuscarinic therapy in the US;Continence Reports;2023-03

4. Bladder Dysfunction in Older Adults: The Botulinum Toxin Option;Drugs & Aging;2022-06

5. Utilization rate and long‐term persistence of combination pharmacotherapy with β3‐agonists and antimuscarinics for overactive bladder refractory to monotherapy in a real‐world setting;Neurourology and Urodynamics;2022-04-14